menu
    • menu

    Company profile for Eikonizo Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The name captures our strategy to use neuroimaging earlier in the drug discovery process to de-risk therapeutic approaches to neurodegeneration. Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative dise...
    The name captures our strategy to use neuroimaging earlier in the drug discovery process to de-risk therapeutic approaches to neurodegeneration. Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eikonizo TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Lab Central, 700 Main Street North Cambridge, MA 02139
    Telephone
    Telephone
    617-302-6817
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eikonizo.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eikonizo-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eikonizo Publishes HDAC6 Inhibitor Data For ALS And FTD
    Eikonizo Publishes HDAC6 Inhibitor Data For ALS And FTD

    09 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251009165881/en/Eikonizo-Therapeutics-Announces-Publication-in-Brain-Demonstrating-Disease-Modifying-Potential-of-Selective-HDAC6-Inhibitors-in-Preclinical-Models-of-ALS-and-FTD

    BUSINESSWIRE
    09 Oct 2025
    Share Share
    Eikon Therapeutics To Present At 43rd Annual JP Morgan Conference
    Eikon Therapeutics To Present At 43rd Annual JP Morgan Conference

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107089765/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    Eikonizo Therapeutics Announces Investment by Novo for EKZ-102
    Eikonizo Therapeutics Announces Investment by Novo for EKZ-102

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241203470313/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Eikon gins up half-a-billion-dollar series B, bolsters C-suite
    Eikon gins up half-a-billion-dollar series B, bolsters C-suite

    06 Jan 2022

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/eikon-therapeutics-snares-500m-series-b-pinning-constellation-biotech-stars-to-its-upper

    FIERCEBIOTECH
    06 Jan 2022
    Share Share
    Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer
    Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer

    29 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210629005418/en

    BUSINESSWIRE
    29 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search